Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ৳19.20, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 21% over the past three years. Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Apr 24
Silco Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 29, 2026 Silco Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 29, 2026 공시 • Jan 26
Silco Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026 Silco Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026 공시 • Nov 25
Silco Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 30, 2025 Silco Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 30, 2025 공시 • Nov 19
Silco Pharmaceuticals Limited announces Annual dividend, payable on February 18, 2026 Silco Pharmaceuticals Limited announced Annual dividend of BDT 0.1100 per share payable on February 18, 2026, ex-date on December 17, 2025 and record date on December 15, 2025. 공시 • Nov 18
Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026 Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026, at 11:30 Central Asia Standard Time. Location: hybrid system:, at registered office premises., Bangladesh 공시 • Nov 11
Silco Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Nov 17, 2025 Silco Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Nov 17, 2025 공시 • Apr 21
Silco Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025 Silco Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025 공시 • Jan 27
Silco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025 Silco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025 공시 • Nov 18
Silco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 21, 2024 Silco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 21, 2024 New Risk • Nov 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Revenue is less than US$5m (৳422m revenue, or US$3.5m). Market cap is less than US$100m (৳1.63b market cap, or US$13.6m). Declared Dividend • Nov 06
Dividend of ৳0.10 announced Shareholders will receive a dividend of ৳0.10. Ex-date: 9th December 2024 Payment date: 16th February 2025 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (66% earnings payout ratio) but not adequately covered by cash flows (92% cash payout ratio). The dividend has increased by an average of 13% per year over the past 4 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 27% to shift the payout ratio to a potentially unsustainable range, which is more than the 23% EPS decline seen over the last 5 years. 공시 • Nov 04
Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025 Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh 공시 • Oct 25
Silco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 31, 2024 Silco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ৳21.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 27% over the past three years. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ৳21.30, the stock trades at a trailing P/E ratio of 51.7x. Average trailing P/E is 31x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 7.5% over the past three years. Reported Earnings • May 02
Third quarter 2024 earnings released: EPS: ৳0.16 (vs ৳0.21 in 3Q 2023) Third quarter 2024 results: EPS: ৳0.16 (down from ৳0.21 in 3Q 2023). Revenue: ৳110.0m (down 12% from 3Q 2023). Net income: ৳17.1m (down 21% from 3Q 2023). Profit margin: 16% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. 공시 • Apr 26
Silco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024 Silco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024 Reported Earnings • Feb 08
Second quarter 2024 earnings released: EPS: ৳0.12 (vs ৳0.15 in 2Q 2023) Second quarter 2024 results: EPS: ৳0.12 (down from ৳0.15 in 2Q 2023). Revenue: ৳104.9m (flat on 2Q 2023). Net income: ৳12.8m (down 19% from 2Q 2023). Profit margin: 12% (down from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ৳19.80, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.8% over the past three years. 공시 • Jan 24
Silco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 30, 2024 Silco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 30, 2024 New Risk • Jan 09
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (157% cash payout ratio). Large one-off items impacting financial results. Revenue is less than US$5m (৳437m revenue, or US$4.0m). Market cap is less than US$100m (৳2.43b market cap, or US$22.2m). Upcoming Dividend • Dec 12
Upcoming dividend of ৳0.30 per share at 1.3% yield Eligible shareholders must have bought the stock before 19 December 2023. Payment date: 12 February 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%). New Risk • Dec 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.43b market cap, or US$22.1m). 공시 • Nov 29
Silco Pharmaceuticals Limited Recommends Cash Dividend for All Shareholders Excluding Directors for the Year Ended June 30, 2023 Silco Pharmaceuticals Limited recommended 3% cash dividend for all shareholders excluding Directors for the year ended June 30, 2023. 공시 • Nov 28
Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024 Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024, at 11:30 Bangladesh Standard Time. Agenda: To approve the Dividend Declaration. 공시 • Nov 27
Silco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 29, 2023 Silco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 29, 2023 공시 • Nov 20
Silco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Nov 26, 2023 Silco Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Nov 26, 2023 New Risk • Jun 15
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ৳418m (US$3.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.47b market cap, or US$22.7m). Buying Opportunity • May 29
Now 22% undervalued Over the last 90 days, the stock is up 4.7%. The fair value is estimated to be ৳31.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has grown by 4.4%. 공시 • Jan 12
Silco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended June 30, 2022 Silco Pharmaceuticals Limited approved 5% cash dividend for the year ended June 30, 2022. Upcoming Dividend • Nov 29
Upcoming dividend of ৳0.50 per share Eligible shareholders must have bought the stock before 06 December 2022. Payment date: 09 February 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.3%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Nov 08
Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022 Silco Pharmaceuticals Limited announced that the Board of Directors has recommended 5% cash dividend for all shareholders excluding Directors only for the year ended June 30, 2022. Buying Opportunity • Jul 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.2%. The fair value is estimated to be ৳29.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last year. Earnings per share has declined by 50%. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 17% share price gain to ৳30.40, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 29% over the past year. Reported Earnings • May 29
Third quarter 2021 earnings released: EPS: ৳0.32 (vs ৳0.25 in 3Q 2020) Third quarter 2021 results: EPS: ৳0.32 (up from ৳0.25 in 3Q 2020). Revenue: ৳188.7m (down 5.1% from 3Q 2020). Net income: ৳33.3m (up 28% from 3Q 2020). Profit margin: 18% (up from 13% in 3Q 2020). The increase in margin was driven by lower expenses. Buying Opportunity • May 26
Now 20% undervalued Over the last 90 days, the stock is up 5.7%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%. Buying Opportunity • May 11
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 1.5%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buying Opportunity • Apr 04
Now 20% undervalued Over the last 90 days, the stock is up 4.4%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 18% share price gain to ৳27.10, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 17% over the past year. Buying Opportunity • Feb 15
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 1.9%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% per annum over the last 3 years. Earnings per share has declined by 25% per annum over the last 3 years. Upcoming Dividend • Dec 14
Upcoming dividend of ৳1.00 per share Eligible shareholders must have bought the stock before 21 December 2021. Payment date: 15 February 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.8%. Within top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%). Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 18% share price gain to ৳30.90, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 44% over the past year. Reported Earnings • Feb 24
Second quarter 2021 earnings released: EPS ৳0.12 (vs ৳0.23 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳121.3m (down 29% from 2Q 2020). Net income: ৳12.4m (down 48% from 2Q 2020). Profit margin: 10% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue. 공시 • Nov 03
Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020 Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Bangladesh Standard Time. Agenda: To recommend cash dividend for the year ended on June 30, 2020. 공시 • Oct 05
Silco Pharmaceuticals Limited Signs First Export Agreement with Zaid Elyas Adil Ltd Silco Pharmaceuticals Limited signed its first export agreement with ZAID ELYAS ADIL LTD, Afghanistan. The Company will export total of 13 different medicines to Afghanistan for next 5 years commencing from August 2020. Total export value (estimated) will be USD 3,80,000.00. First export value (as per PI) will be USD 26,780.00 against 13 different medicines to Afghanistan and estimated profit will be 30% against the export. 공시 • Jul 06
Silco Pharmaceuticals Limited to Report Q3, 2020 Results on Jun 29, 2020 Silco Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jun 29, 2020